News

News Subscription

Jan 28. 2025
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
Read more
Download
Jan 08. 2025
Basilea provides portfolio update and outlook
Read more
Download
Dec 23. 2024 / Ad hoc announcement
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Read more
Download
Dec 16. 2024 / Ad hoc announcement
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Oct 10. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year
Read more
Download
Sep 24. 2024
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Read more
Download
Sep 19. 2024 / Ad hoc announcement
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Read more
Download
Sep 06. 2024 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
Read more
Download
Aug 27. 2024 / Ad hoc announcement
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
Read more
Download
Aug 21. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download